Gene Therapies for Hemoglobinopathies

Date & Location
Tuesday, February 4, 2025, 11:30 AM – 12:30 PM, A Live Webinar
Overview
In the last few years, gene therapies have started to transform care for some blood disorders—and the revolution is just beginning. In this webinar, attendees will learn about gene therapies available for hemoglobinopathies, including FDA approved treatments and therapies available through clinical trials. We will also discuss the steps patients take to prepare for gene therapy and what they can expect after treatment.
Registration
Registration for all practitioners – free
To register for this activity, please click HERE.
Credits
AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Participation Credit (1.00 hours)
Target Audience
Specialties – Adolescent Medicine, Family Medicine & Community Health, Genetics & Genomics, Hematology, Pediatrics, Preventative Medicine & Nutrition
Professions – Fellow/Resident, Non-Physician, Physician
Objectives
At the conclusion of this activity, learners should be able to:
Describe current and future gene therapies for hemoglobinopathies Review the different types of gene therapies Assess whether a patient may be a good candidate for gene therapy Discuss what patients can expect before, during, and after treatment
Accreditation
In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
American Medical Association (AMA)
Stanford Medicine designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.